Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials

被引：2
作者：
Dzimitrowicz, Hannah E. [1 ]
Armstrong, Andrew J. [1 ]
机构：
[1] Duke Univ, Dept Med, Duke Canc Inst Ctr Prostate & Urol Canc, Durham, NC 27708 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 08期
关键词：
ANDROGEN DEPRIVATION THERAPY; QUALITY-OF-LIFE; ABIRATERONE;
D O I：
10.1200/JCO.21.02504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：807 / +
页数：5
相关论文
共 16 条
  • [1] Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
    Agarwal, Neeraj
    McQuarrie, Kelly
    Bjartell, Anders
    Chowdhury, Simon
    Pereira de Santana Gomes, Andrea J.
    Chung, Byung Ha
    Ozguroglu, Mustafa
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Uemura, Hirotsugu
    Ye, Dingwei
    Given, Robert
    Cella, David
    Basch, Ethan
    Miladinovic, Branko
    Dearden, Lindsay
    Deprince, Kris
    Naini, Vahid
    Lopez-Gitlitz, Angela
    Chi, Kim N.
    [J]. LANCET ONCOLOGY, 2019, 20 (11) : 1518 - 1530
  • [2] Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Armstrong, A. J.
    Iguchi, T.
    Azad, A. A.
    Szmulewitz, R. Z.
    Holzbeierlein, J.
    Villers, A.
    Alcaraz, A.
    Alekseev, B. Y.
    Shore, N. D.
    Petrylak, D. P.
    Rosbrook, B.
    Zohren, F.
    Yamada, S.
    Haas, G. P.
    Stenzl, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1300 - S1301
  • [3] Reliability of adverse symptom event reporting by clinicians
    Atkinson, Thomas M.
    Li, Yuelin
    Coffey, Charles W.
    Sit, Laura
    Shaw, Mary
    Lavene, Dawn
    Bennett, Antonia V.
    Fruscione, Mike
    Rogak, Lauren
    Hay, Jennifer
    Goenen, Mithat
    Schrag, Deborah
    Basch, Ethan
    [J]. QUALITY OF LIFE RESEARCH, 2012, 21 (07) : 1159 - 1164
  • [4] Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Basch, Ethan
    Reeve, Bryce B.
    Mitchell, Sandra A.
    Clauser, Steven B.
    Minasian, Lori M.
    Dueck, Amylou C.
    Mendoza, Tito R.
    Hay, Jennifer
    Atkinson, Thomas M.
    Abernethy, Amy P.
    Bruner, Deborah W.
    Cleeland, Charles S.
    Sloan, Jeff A.
    Chilukuri, Ram
    Baumgartner, Paul
    Denicoff, Andrea
    St Germain, Diane
    O'Mara, Ann M.
    Chen, Alice
    Kelaghan, Joseph
    Bennett, Antonia V.
    Sit, Laura
    Rogak, Lauren
    Barz, Allison
    Paul, Diane B.
    Schrag, Deborah
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09):
  • [5] Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
    Chi, Kim N.
    Chowdhury, Simon
    Bjartell, Anders
    Byung Ha Chung
    Gomes, Andrea J. Pereira de Santana
    Given, Robert
    Juarez, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Brookman-May, Sabine
    Mundle, Suneel D.
    McCarthy, Sharon A.
    Larsen, Julie S.
    Sun, Weili
    Bevans, Katherine B.
    Zhang, Ke
    Bandyopadhyay, Nibedita
    Agarwal, Neeraj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (20) : 2294 - +
  • [6] Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
    Chi, Kim N.
    Protheroe, Andrew
    Rodriguez-Antolin, Alfredo
    Facchini, Gaetano
    Suttman, Henrik
    Matsubara, Nobuaki
    Ye, Zhangqun
    Keam, Bhumsuk
    Damiao, Ronaldo
    Li, Tracy
    McQuarrie, Kelly
    Jia, Bin
    De Porre, Peter
    Martin, Jsaon
    Todd, Mary B.
    Fizazi, Karim
    [J]. LANCET ONCOLOGY, 2018, 19 (02) : 194 - 206
  • [7] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    Sulur, Giri
    Luna, Yesenia
    Li, Susan
    Mundle, Suneel
    Chi, Kim N.
    [J]. LANCET ONCOLOGY, 2019, 20 (05) : 686 - 700
  • [8] How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30
    Fromme, EK
    Eilers, KM
    Mori, M
    Hsieh, YC
    Beer, TM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (17) : 3485 - 3490
  • [9] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
    Kyriakopoulos, Christos E.
    Chen, Yu-Hui
    Carducci, Michael A.
    Liu, Glenn
    Jarrard, David F.
    Hahn, Noah M.
    Shevrin, Daniel H.
    Dreicer, Robert
    Hussain, Maha
    Eisenberger, Mario
    Kohli, Manish
    Plimack, Elizabeth R.
    Vogelzang, Nicholas J.
    Picus, Joel
    Cooney, Matthew M.
    Garcia, Jorge A.
    DiPaola, Robert S.
    Sweeney, Christopher J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) : 1080 - +
  • [10] Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
    Morgans, Alicia K.
    Chen, Yu-Hui
    Sweeney, Christopher J.
    Jarrard, David F.
    Plimack, Elizabeth R.
    Gartrell, Benjamin A.
    Carducci, Michael A.
    Hussain, Maha
    Garcia, Jorge A.
    Cella, David
    DiPaola, Robert S.
    Patrick-Miller, Linda J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) : 1088 - +
12